Back to News
Market Impact: 0.25
IBA Treats First Patient In ConformalFLASH Head And Neck Cancer Trial
Source: Nasdaq
Healthcare & BiotechTechnology & InnovationProduct Launches
Ion Beam Applications said the first patient was treated at Penn Medicine in C-FLASH-01, the first human feasibility study of its investigational ConformalFLASH proton therapy. This is an early clinical milestone; the article provides no efficacy results or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
IBAB0.60
More News
- Meta put out an ambitious roadmap to Muse monetization after strong quarter and guide
- Critical web security flaws spark global alarm as Google, OpenAI and Amazon respond
- Futures orbit around SpaceX as Tesla merger talk cheers investors
- Elon Musk Thinks $3.5 Trillion Tesla-SpaceX Mashup Is a Good Idea
- World leaders warn against security flaw found in PHP computer programming
- SpaceX gives the AI trade a shot in the arm. What it means for our stocks
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Index and ETF Holdings Data for AI Research
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)